Objective To investigate the effects of exercise on the activity of heme oxygenase-1 ( HO-1 ) and the expression of HO-1 mRNA and the mechanisms involved in the vascular smooth muscle tissue of rats with spontaneous hypertension (SHR). Methods Twelve male Wistar rats with normal blood pressure were used as control group ( group C ).Another 24 male rats with SHR were randomly assigned to one of 2 experimental groups ( 12 rats per group):an SHR group (group S) and an SHR treated group (group T).Rats in group T were treated with 60 minutes of unloaded swimming exercise 6 times a week for 9 weeks.Their blood pressure was measured once a week.After the nine weeks HO-1 activity as well as the expression of HO-1 mRNA in vascular smooth muscle and the concentration of carbon monoxide in plasma were measured. Results After the 9 weeks of training,average systolic blood pressure in group T was close to that of group C.The systolic blood pressure of group S continued to rise,and was significantly higher than that of the other 2 groups at each time point.Average HO-1 activity in group S (637.94 ± 73.637 ) reduced significantly compared with that of group C (786.20 ± 74.698) or with that of group T ( 1036.53 ± 140.63 ).That of group T was significantly higher than that of group C.The average expression of HO1 mRNA in group S (80.85 ± 6.953 ) was significantly higher than that of group C (45.15 ± 7.651 ) and lower than that of group T (90.70 ± 11.20),and the differences were statistically significant at the 5％ level of confidence.The average level of expression of HO-1 mRNA in the T group was significantly higher than that of group C.The plasma carbon monoxide content of S group was significantly lower than that of groups C and T. Conclusions Exercise can enhance the activity of HO-1 and the expression of HO-1 mRNA in vascular smooth muscle in rats with SHR to reduce blood pressure.

BACKGROUND:Proto-oncogene c-Src plays an important role in regulating cardiovascular diseases such as hypertension. At present, there were no studies concerning exercise intervention effects on c-Src expression in aortic endothelial cels so as to regulate hypertension. OBJECTIVE: To observe the effects of aerobic exercise on c-Src mRNA expression and c-Src activity in the aorta blood vessel endothelial cels of spontaneous hypertensive rats. METHODS: A total of 8 male Wistar rats were considered as normal control group. Sixteen spontaneous hypertensive rats were randomly assigned to 8 rats as spontaneous hypertension group and 8 rats as spontaneous hypertension exercise group. Rats in the spontaneous hypertension exercise group carried on 90 minutes unloaded aerobic swimming every day, 6 days a week, for 8 weeks. The rats in the normal control group and spontaneous hypertension group did not swim. Blood pressure of rats was measured once a week. 8 weeks later, the c-Src mRNA expression and c-Src activity were determined in aortic vascular endothelial cels of rats in each group. RESULTS AND CONCLUSION: Compared with spontaneous hypertension group, blood pressure was lower, but c-Src mRNA expression and c-Src activity were significantly higher in the spontaneous hypertension exercise group. The c-Src activity and c-Src mRNA expression were higher in the spontaneous hypertension exercise group than normal control group and spontaneous hypertension group (P < 0.01). Results indicated that aerobic exercise can promote the increase in c-Src activity and c-Src mRNA expression in aortic endothelial cels of spontaneous hypertensive rats.

Objective To explore the influence of icotinib in the apoptosis of the human salivary adenoid cystic carcinoma cells ACC-M, and to clarify the mechanism of icotinib for the treatment of salivary adenoid cystic carcinoma.Methods The ACC-M cells were randomly divided into control group,2,4,8μmo1·L-1 icotinib groups,p38-MAPK inhibitor SB203580 (20μmol· L-1 )group,SB203580 (20 μmol· L-1 )+4μmo1 · L-1 icotinib group;the cells were collected 4 h after treatment.The viability of ACC-M cells was measured by MTT assay.The apoptosis of ACC-M cells was assessed by caspase-3 activity kit. The expression of p-p38-MAPK protein was determined by Western blotting analysis.Results Compared with control group,the inhibitory rates of growth of the ACC-M cells in icotinib groups were significantly decreased (P<0.05 ), and the activities of caspase-3 were increased (P<0.05),and the expression levels of p-p38-MAPK were significantly increased (P<0.05).Compared with 4μmo1·L-1 icotinib group,the expression level of p-p38-MAPK in SB203580+icotinib group were decreased (P < 0.05 ), and the activity of caspase-3 was decreased dramatically (P < 0.05 ). Conclusion Icotinib may induce the apoptosis of ACC-M cells through the activation of p38-MAPK signaling pathway.

Objective:To construct an outpatient counseling record sheet of breastfeeding based on Delphi method, so as to standardize the consultation process of breastfeeding clinics.Methods:Through literature analysis and discussion of the research group, the expert letter questionnaire was designed by themselves. From September to October 2020, two rounds of Delphi letter inquiries were conducted with 16 experts in Hangzhou to determine the outpatient counseling record sheet of breastfeeding.Results:The positive coefficients of two rounds of expert letter inquiries were 100%, the expert authority coefficients were respectively 0.93 and 0.95, and the Kendall's coefficient of concordance were 0.135-0.204 and 0.234-0.563 ( P< 0.05) . The final counseling record sheet constructed included 8 first-level items, 99 second-level items and 94 third-level items. Conclusions:Letter consulting experts have high enthusiasm, high degree of authority and good coordination. The breastfeeding clinic consultation record based on the Delphi method is highly scientific and practical, which can be applied to breastfeeding clinics in various maternal and infant medical institutions.

Objective:To explore the status quo of nurses' recognition of nursing adverse event reporting barrier and analyze its influencing factors.Methods:From September to October 2021, 2 347 nurses from 73 Class Ⅱ and Class Ⅲ medical institutions in Tianjin were selected as research subjects by convenience sampling. Questionnaire survey was conducted with the General Information Questionnaire, Adverse Event Reporting Barrier Scale and Patient Safety Culture Assessing Scale. Through univariate analysis, Spearman correlation analysis and multiple linear regression analysis, the factors influencing nurses' recognition of reporting barrier were explored.Results:A total of 2 347 questionnaires were collected and 2 335 valid ones were collected. Among 2 335 nurses, the total score of the Adverse Event Reporting Barrier Scale was 77.0 (69.0, 86.0), and the total score of safety culture attitude was 104.0 (99.0, 110.0). Spearman correlation analysis showed that there was a negative correlation between the total score of nurses' recognition of reporting barriers and the total score of safety culture attitude, and the difference was statistically significant ( r=-0.328, P<0.01). Multiple linear regression analysis showed that the motivation mechanism, reporting form of adverse events, job position, and safety culture attitude of nurses were the influencing factors of the recognition of reporting barriers, with a statistical difference ( P<0.05), which explained 13.1% of the variation. Conclusions:Motivation mechanism, reporting form of adverse events, job position, safety culture attitude of nurses are the influencing factors of recognition of reporting barriers. Nursing managers should take positive measures to create a non-punitive culture, optimize the adverse event reporting system, strengthen the training of adverse event reporting, and improve the recognition of nurses in reporting barriers, so as to increase the reporting rate of nursing adverse events.

BACKGROUND: Given the general unavailability, common adverse effects, and complicated administration of tetracycline, the clinical application of classic bismuth quadruple therapy (BQT) is greatly limited. Whether minocycline can replace tetracycline for Helicobacter pylori ( H . pylori ) eradication is unknown. We aimed to compare the eradication rate, safety, and compliance between minocycline- and tetracycline-containing BQT as first-line regimens. METHODS: This randomized controlled trial was conducted on 434 naïve patients with H . pylori infection. The participants were randomly assigned to 14-day minocycline-containing BQT group (bismuth potassium citrate 110 mg q.i.d., esomeprazole 20 mg b.i.d., metronidazole 400 mg q.i.d., and minocycline 100 mg b.i.d.) and tetracycline-containing BQT group (bismuth potassium citrate/esomeprazole/metronidazole with doses same as above and tetracycline 500 mg q.i.d.). Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed at 4-8 weeks after eradication to evaluate outcome. We used a noninferiority test to compare the eradication rates of the two groups. The intergroup differences were evaluated using Pearson chi-squared or Fisher's exact test for categorical variables and Student's t -test for continuous variables. RESULTS: As for the eradication rates of minocycline- and tetracycline-containing BQT, the results of both intention-to-treat (ITT) and per-protocol (PP) analyses showed that the difference rate of lower limit of 95% confidence interval (CI) was >-10.0% (ITT analysis: 181/217 [83.4%] vs . 180/217 [82.9%], with a rate difference of 0.5% [-6.9% to 7.9%]; PP analysis: 177/193 [91.7%] vs . 176/191 [92.1%], with a rate difference of -0.4% [-5.6% to 6.4%]). Except for dizziness more common (35/215 [16.3%] vs . 13/214 [6.1%], P = 0.001) in minocycline-containing therapy groups, the incidences of adverse events (75/215 [34.9%] vs . 88/214 [41.1%]) and compliance (195/215 [90.7%] vs . 192/214 [89.7%]) were similar between the two groups. CONCLUSION: The eradication efficacy of minocycline-containing BQT was noninferior to tetracycline-containing BQT as first-line regimen for H . pylori eradication with similar safety and compliance. TRIAL REGISTRATION ClinicalTrials.gov, ChiCTR 1900023646.
Humans ; Bismuth/therapeutic use* ; Metronidazole/therapeutic use* ; Esomeprazole/pharmacology* ; Minocycline/pharmacology* ; Helicobacter pylori ; Potassium Citrate/therapeutic use* ; Anti-Bacterial Agents ; Tetracycline/adverse effects* ; Helicobacter Infections/drug therapy* ; Drug Therapy, Combination ; Amoxicillin